A trial investigating the efficacy and safety of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen - BEGIN : BB T1

OVO NORDISK0 sites426 target enrollmentDecember 28, 2009

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: OVO NORDISK
Enrollment: 426
Status: Active, not recruiting
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 28, 2009

End Date

TBD

Last Updated

14 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

OVO NORDISK

Eligibility Criteria

Inclusion Criteria

•1\. Informed consent obtained before any trial\-related activities. (Trial related activities are defined as any procedure that would not have been performed during normal management of the subject) 2\. Males or females, ≥ 18 years of age (≥ 20 years for Japan) 3\. Type 1 diabetes mellitus (diagnosed clinically) ≥ 12 months 4\. Current treatment with any basal/bolus insulin regimen for at least 12 months prior to Visit 1 5\. HbA1c ≤ 10\.0 % by central laboratory analysis 6\. BMI ≤ 35\.0 kg/m2 7\. Ability and willingness to adhere to the protocol including performance of self measured plasma glucose (SMPG) profiles according to the protocol
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

•Use within the last 3 months prior to Visit 1 of any other antidiabetic glucose lowering drug than insulin 2\. Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic corticosteroids, beta\-blockers, MAO inhibitors 3\. Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA)2 class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty 4\. Uncontrolled treated/untreated severe hypertension (systolic blood pressure ≥ 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure ≥ 100 mmHg) 5\. Impaired liver function, defined as ALAT ≥ 2\.5 times upper limit of normal (one re\-test analysed at the central laboratory within a week from receipt of the result is permitted with the result of the last sample being conclusive) 6\. Impaired renal function defined as serum\-creatinine ≥ 180 μmol/L (≥ 2\.0 mg/dl); one re\-test within a week from receipt of the result is permitted. Last sample will be conclusive 7\. Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic episode during the last 12 months) or hypoglycaemic unawareness or hospitalisation for diabetic ketoacidosis during the previous 6 months 8\. Proliferative retinopathy or maculopathy requiring treatment according to the Investigator 9\. Pregnancy, breast\-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements (for UK: Adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, sterilisation, intrauterine device or intrauterine system, or consistent use of barrier methods) 10\. Cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer) 11\. Any clinically significant disease or disorder, except for conditions associated with type 1 diabetes, which in the Investigator s opinion could interfere with the results of the trial 12\. Mental incapacity, psychiatric disorder, unwillingness or language barriers precluding adequate understanding or co\-operation, including subjects not able to read or write 13\. Previous participation in this trial. Participation is defined as randomised. Re\-screening of screening failures is allowed only once within the limits of the recruitment period 14\. Known or suspected allergy to any of the trial products or related products 15\. Receipt of any investigational drug within one month prior to screening visit (Visit 1\) 16\. Donation of blood within one month prior to screening visit (Visit 1\) 17\. Participation in other trials within one month prior to screening visit (Visit 1\). For Brazil only: receipt of any investigational drug within one year prior to screening visit (visit 1\), unless there is a direct benefit to the research subject at the investigator\`s discretion 18\. Known or suspected abuse of alcohol, narcotics or illicit drugs 19\. Previous treatment with insulin 454 20\. Anticipated significant lifestyle changes during the study, e.g. shift work (including permanent night/evening shift workers), as well as highly variable eating habits